Identification of ABR‐215050 as lead second generation quinoline‐3‐carboxamide anti‐angiogenic agent for the treatment of prostate cancer

Linomide, Figure 1, produces robust and consistent in vivo growth inhibition of prostate cancer models via its anti‐angiogenic activity and inhibition of autoimmune encephalomyelitis models of multiple sclerosis (MS). MS clinical trials were discontinued because of unacceptable toxicity, due to dose‐dependent induction of proinflammation.

[1]  L. Devy,et al.  Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis , 2002, Biological Procedures Online.

[2]  Alberto Mantovani,et al.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.

[3]  C. Teunissen,et al.  Macrophages and neurodegeneration , 2005, Brain Research Reviews.

[4]  G. Hedlund,et al.  Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. , 2004, Journal of medicinal chemistry.

[5]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[6]  A. Klein-Szanto,et al.  CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. , 2003, Cancer research.

[7]  J. Isaacs,et al.  Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. , 2001, Cancer research.

[8]  J. Isaacs,et al.  Modified synthesis and antiangiogenic activity of linomide. , 2001, Bioorganic & medicinal chemistry letters.

[9]  J. Wolinsky,et al.  Linomide in relapsing and secondary progressive MS , 2000, Neurology.

[10]  F. Lublin,et al.  Linomide in relapsing and secondary progressive MS , 2000, Neurology.

[11]  G. Hedlund,et al.  Linomide (roquinimex) affects the balance between pro‐ and anti‐inflammatory cytokines in vitro in multiple sclerosis , 1998, Acta neurologica Scandinavica.

[12]  G. Hedlund,et al.  Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines , 1998, Journal of Neuroimmunology.

[13]  J. Nelson,et al.  Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  J. Isaacs,et al.  Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. , 1997, The Journal of urology.

[15]  B. Foster,et al.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.

[16]  J. Isaacs,et al.  Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. , 1997, Cancer research.

[17]  J. Isaacs,et al.  Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. , 1996, Cancer research.

[18]  J. Isaacs,et al.  Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. , 1995, Cancer research.

[19]  P. Snyder,et al.  Pathologic Features of Naturally Occurring Juvenile Polyarteritis in Beagle Dogs , 1995, Veterinary pathology.

[20]  J. Isaacs,et al.  Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers , 1995, The Prostate.

[21]  R W Veltri,et al.  Implication of cell kinetic changes during the progression of human prostatic cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  J. Isaacs,et al.  Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. , 1995, Cancer research.

[23]  A. Ben-nun,et al.  Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide , 1993, Annals of neurology.

[24]  D. Karussis,et al.  Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Isaacs,et al.  The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. , 1992, Cancer research.

[26]  N. Kyprianou,et al.  Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. , 1990, Cancer research.

[27]  William B. Isaacs,et al.  Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers , 1986 .